Furthermore, individuals receiving intravenous abatacept exhibited a relapse-free survival rate of 48% at 12 months, in contrast to 31% for those receiving a placebo.15Our research uncovered that employing a TNF inhibitor and abatacept for the management of GCA yielded no beneficial outcomes. This evidence concerns the gene TNF and temporal arteritis.